Botulinum Toxin Type A in the Treatment of Dermatochalasis: An Open-Label, Randomized, Dose-Comparison Study
July 2006 | Volume 5 | Issue 7 | Original Article | 596 | Copyright © July 2006
Joel L. Cohen MD, Steven H. Dayan MD FACS
Objective: To compare the efficacy and safety of 2 doses of botulinum toxin type A in the treatment of dermatochalasis.
Methods: Forty patients with mild to moderate dermatochalasis were randomly assigned to receive 1 of 2 doses of botulinum
toxin type A in the lateral infrabrow—4 U/brow or 6 U/brow—and followed up for 20 weeks.
Results: Investigator assessment showed the proportion of responders (?1 grade improvement in severity of dermatochalasis
on a scale of none, mild, moderate, or severe) at week 2 was 32% with 4 U and 47% with 6 U. Compared with the lower
dose group, the higher dose group also reported a greater degree of improvement, significantly higher ratings for feelings of
attractiveness and feelings of satisfaction with appearance, and a higher incidence of satisfaction.
Conclusion: Single-site injection of botulinum toxin type A in the lateral infrabrow can offer effective treatment for mild to
moderate upper eyelid dermatochalasis.